Osteopontin and Interleukin-8 Expression is Independently Associated with Prostate Cancer Recurrence

Overview

Journal Clin Cancer Res

Specialty Oncology

Date 2008 Jul 3

PMID 18593988

Citations 35

Authors

Daniel J Caruso

Adrienne J K Carmack

Vinata B Lokeshwar

Robert C Duncan

Mark S Soloway

Bal L Lokeshwar

Affiliations

Soon will be listed here.

Abstract

Purpose: Lack of reliable biomarkers limits accurate prediction of prostate-specific antigen biochemical recurrence (disease progression) in prostate cancer. The two inflammatory chemokines, osteopontin and interleukin-8 (IL-8), are associated with tumor angiogenesis and metastasis. We investigated whether osteopontin and IL-8 expression in prostate cancer correlates with disease progression.

Experimental Design: Archival prostatectomy specimens (n = 103) were obtained from patients with minimum 72-month follow-up. Osteopontin and IL-8 expression was evaluated by immunohistochemistry and graded for intensity and the area. Association of osteopontin and IL-8 staining with biochemical recurrence was evaluated by univariate and multivariate models.

Results: In tumor cells, osteopontin and IL-8 staining was higher in the recurred group (203.2 +/- 78.4; 181.1 +/- 89.3) than in the nonrecurred group (122.7 +/- 76.6; 96.4 +/- 85.6; P < 0.001). Higher osteopontin and IL-8 staining was also observed in benign areas adjacent to tumor in the recurred group, than in nonrecurred group. In univariate analysis, except age, all preoperative and postoperative variables and osteopontin and IL-8 staining scores were significantly associated with biochemical recurrence (P < 0.05). In multivariate analysis, margin status and osteopontin staining independently associated with biochemical recurrence within 72 months. Osteopontin, either alone or with IL-8 and seminal vesicle invasion, was a significant variable in predicting biochemical recurrence within 24 months. Osteopontin and IL-8 staining predicted recurrence with high sensitivity (75.5%; 73.6%) and specificity (76%; 70.6%).

Conclusion: In prostatectomy specimens, osteopontin expression is independently associated with biochemical recurrence. Both osteopontin and IL-8 may be predictors of early disease progression.

Citing Articles

Is Osteopontin a Good Marker for Bone Metastasis in Canine Mammary Gland Tumor and Prostate Cancer?.

Grisoni Sanchez C, Figueiredo M, de Sartori Camargo L, Benevenuto L, Lacerda Z, Fonseca-Alves C Animals (Basel). 2023; 13(20).

PMID: 37893935 PMC: 10603680. DOI: 10.3390/ani13203211.

IL-8 Produced Via Bidirectional Communication Between Prostate Cancer and M2 Macrophages as a Potential Diagnostic and Prognostic Biomarker.

Fan H, Tang Z, Tian Y, Lv Q, Zeng F Technol Cancer Res Treat. 2023; 22:15330338231177809.

PMID: 37226533 PMC: 10226307. DOI: 10.1177/15330338231177809.

MicroRNA-106a suppresses prostate cancer proliferation, migration and invasion by targeting tumor-derived IL-8.

Shen P, Sun G, Zhao P, Dai J, Zhang X, Zhao J Transl Cancer Res. 2022; 9(5):3507-3517.

PMID: 35117716 PMC: 8799044. DOI: 10.21037/tcr.2020.03.70.

Loss of CMTM6 promotes DNA damage-induced cellular senescence and antitumor immunity.

Wang H, Fan Y, Chen W, Lv Z, Wu S, Xuan Y Oncoimmunology. 2022; 11(1):2011673.

PMID: 35024247 PMC: 8747516. DOI: 10.1080/2162402X.2021.2011673.

Blood-Derived Biomarkers of Diagnosis, Prognosis and Therapy Response in Prostate Cancer Patients.

Balazs K, Antal L, Safrany G, Lumniczky K J Pers Med. 2021; 11(4).

PMID: 33924671 PMC: 8070149. DOI: 10.3390/jpm11040296.

References

Cookson M, Aus G, Burnett A, Canby-Hagino E, DAmico A, Dmochowski R . Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in.... J Urol. 2007; 177(2):540-5. DOI: 10.1016/j.juro.2006.10.097. View

Singh M, Ananthula S, Milhorn D, Krishnaswamy G, Singh K . Osteopontin: a novel inflammatory mediator of cardiovascular disease. Front Biosci. 2006; 12:214-21. DOI: 10.2741/2059. View

Araki S, Omori Y, Lyn D, Singh R, Meinbach D, Sandman Y . Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer. Cancer Res. 2007; 67(14):6854-62. DOI: 10.1158/0008-5472.CAN-07-1162. View

Michaud D, Daugherty S, Berndt S, Platz E, Yeager M, Crawford E . Genetic polymorphisms of interleukin-1B (IL-1B), IL-6, IL-8, and IL-10 and risk of prostate cancer. Cancer Res. 2006; 66(8):4525-30. DOI: 10.1158/0008-5472.CAN-05-3987. View

Bland J, Altman D . Survival probabilities (the Kaplan-Meier method). BMJ. 1998; 317(7172):1572. PMC: 1114388. DOI: 10.1136/bmj.317.7172.1572. View

Gravallese E . Osteopontin: a bridge between bone and the immune system. J Clin Invest. 2003; 112(2):147-9. PMC: 164297. DOI: 10.1172/JCI19190. View

Cohen B, Gomez P, Omori Y, Duncan R, Civantos F, Soloway M . Cyclooxygenase-2 (COX-2) expression is an independent predictor of prostate cancer recurrence. Int J Cancer. 2006; 119(5):1082-7. DOI: 10.1002/ijc.21749. View

Lokeshwar V, Habuchi T, Grossman H, Murphy W, Hautmann S, Hemstreet 3rd G . Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology. 2006; 66(6 Suppl 1):35-63. DOI: 10.1016/j.urology.2005.08.064. View

Braeckman J, Michielsen D . Prognostic factors in prostate cancer. Recent Results Cancer Res. 2007; 175:25-32. DOI: 10.1007/978-3-540-40901-4_3. View

10.

Kim S, Uehara H, Karashima T, McCarty M, Shih N, Fidler I . Expression of interleukin-8 correlates with angiogenesis, tumorigenicity, and metastasis of human prostate cancer cells implanted orthotopically in nude mice. Neoplasia. 2001; 3(1):33-42. PMC: 1505029. DOI: 10.1038/sj.neo.7900124. View

11.

Rangaswami H, Bulbule A, Kundu G . Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol. 2006; 16(2):79-87. DOI: 10.1016/j.tcb.2005.12.005. View

12.

Sodek J, Ganss B, McKee M . Osteopontin. Crit Rev Oral Biol Med. 2000; 11(3):279-303. DOI: 10.1177/10454411000110030101. View

13.

Forootan S, Foster C, Aachi V, Adamson J, Smith P, Lin K . Prognostic significance of osteopontin expression in human prostate cancer. Int J Cancer. 2005; 118(9):2255-61. DOI: 10.1002/ijc.21619. View

14.

Rudland P, Platt-Higgins A, El-Tanani M, de Silva Rudland S, Barraclough R, Winstanley J . Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res. 2002; 62(12):3417-27. View

15.

Attur M, Dave M, Clancy R, Patel I, Abramson S, Amin A . Functional genomic analysis in arthritis-affected cartilage: yin-yang regulation of inflammatory mediators by alpha 5 beta 1 and alpha V beta 3 integrins. J Immunol. 2000; 164(5):2684-91. DOI: 10.4049/jimmunol.164.5.2684. View

16.

Amling C . Biochemical recurrence after localized treatment. Urol Clin North Am. 2006; 33(2):147-59, v. DOI: 10.1016/j.ucl.2005.12.002. View

17.

Canto E, Shariat S, Slawin K . Biochemical staging of prostate cancer. Urol Clin North Am. 2003; 30(2):263-77. DOI: 10.1016/s0094-0143(02)00183-0. View

18.

Yang H, Woodson K, Taylor P, Pietinen P, Albanes D, Virtamo J . Genetic variation in interleukin 8 and its receptor genes and its influence on the risk and prognosis of prostate cancer among Finnish men in a large cancer prevention trial. Eur J Cancer Prev. 2006; 15(3):249-53. DOI: 10.1097/01.cej.0000199504.07947.e7. View

19.

Khodavirdi A, Song Z, Yang S, Zhong C, Wang S, Wu H . Increased expression of osteopontin contributes to the progression of prostate cancer. Cancer Res. 2006; 66(2):883-8. DOI: 10.1158/0008-5472.CAN-05-2816. View

20.

Fedarko N, Jain A, Karadag A, Van Eman M, Fisher L . Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res. 2001; 7(12):4060-6. View